COMMUNIQUÉ DE PRESSE publié le 30/01/2023 à 14:30, il y a 3 années 2 mois Jaguar Health Engages Former FDA Gastroenterology Division Deputy Director Andrew Mulberg, M.D. to Bolster Company's Regulatory Expertise
COMMUNIQUÉ DE PRESSE publié le 27/01/2023 à 22:15, il y a 3 années 2 mois Jaguar Health Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
COMMUNIQUÉ DE PRESSE publié le 26/01/2023 à 14:30, il y a 3 années 2 mois Jaguar Health Provides Updates Regarding Company's Focus on Rare and Orphan Disease Indications in the U.S. & Europe
COMMUNIQUÉ DE PRESSE publié le 25/01/2023 à 14:30, il y a 3 années 2 mois Jaguar Health Announces Completion of Key Milestone in Process of Establishing Indena S.p.A. as a Reliable Approved Crofelemer Manufacturer
COMMUNIQUÉ DE PRESSE publié le 23/01/2023 à 14:30, il y a 3 années 3 mois Jaguar Health Announces Establishment of Board of Directors for Newly Formed Joint Venture Magdalena Biosciences
COMMUNIQUÉ DE PRESSE publié le 20/01/2023 à 18:45, il y a 3 années 3 mois Jaguar Health Reports Voting Results from January 2023 Special Meeting of Stockholders
COMMUNIQUÉ DE PRESSE publié le 20/01/2023 à 14:30, il y a 3 années 3 mois Jaguar Health to Present at Lytham Partners Investor Select Conference on January 31st
COMMUNIQUÉ DE PRESSE publié le 12/01/2023 à 01:10, il y a 3 années 3 mois REMINDER: Jaguar Health to Hold Investor Webcast Thursday, January 12th at 10:30 AM EST to Highlight Unmet Medical Need of Cancer Therapy-related Diarrhea and Jaguar’s Mental Health Entheogen Therapeutics Initiative (ETI) to Discover Novel Therapies Der
COMMUNIQUÉ DE PRESSE publié le 11/01/2023 à 14:30, il y a 3 années 3 mois Sandra M. Swain, MD, FACP, FASCO Joins Jaguar Health's Scientific Advisory Board
COMMUNIQUÉ DE PRESSE publié le 10/01/2023 à 14:45, il y a 3 années 3 mois Jaguar Health to Hold Investor Webcast Thursday, January 12th at 10:30 AM EST to Highlight Unmet Medical Need of Cancer Therapy-related Diarrhea and Jaguar's Mental Health Entheogen Therapeutics Initiative (ETI) to Discover Novel Therapies Derived from Ps
Publié le 24/04/2026 à 18:48, il y a 1 heure 49 minutes Laboratoires Euromedis - Communiqué résultat 2025
Publié le 24/04/2026 à 18:00, il y a 2 heures 37 minutes SMTPC - Communiqué sur la mise à disposition du Rapport annuel 2025
Publié le 24/04/2026 à 17:45, il y a 2 heures 52 minutes Imerys-04-2026-information-share-capital-and-voting-rights-as-of-31-March-2026
Publié le 24/04/2026 à 15:00, il y a 5 heures 37 minutes Norsemont Reports Significant Copper, Lead & Zinc Values in Three Choquelimpie Drill Holes
Publié le 24/04/2026 à 15:00, il y a 5 heures 37 minutes First Canadian Graphite Appoints Scott Kelly As Chief Financial Officer
Publié le 24/04/2026 à 14:30, il y a 6 heures 7 minutes Jaguar Health Announces Acceptance of two Late-Breaking Abstracts for Liquid Oral Crofelemer Treatment of Intestinal Failure in Pediatric Patients at the European Society for Pediatric Gastroenterology, Hepatology & Nutrition (ESPGHAN)
Publié le 24/04/2026 à 14:00, il y a 6 heures 37 minutes Datametrex Expands Patent Monetization Strategy Adding Quantum-Resilient Encryption Technologies
Publié le 24/04/2026 à 13:30, il y a 7 heures 7 minutes Alset AI Announces Closing of Second Tranche of Loan Transaction of up to $3 Million
Publié le 24/04/2026 à 18:30, il y a 2 heures 7 minutes EUROPLASMA: Tirage de 400 obligations convertibles en actions nouvelles pour un montant nominal de 2M€
Publié le 24/04/2026 à 18:12, il y a 2 heures 24 minutes EQS-Adhoc: clearvise AG reviews dividend proposal in line with its dividend strategy and postpones Annual General Meeting
Publié le 24/04/2026 à 18:07, il y a 2 heures 30 minutes DEAG sets new records for revenue and earnings in financial year 2025 – excellently positioned for long-term growth
Publié le 24/04/2026 à 18:05, il y a 2 heures 31 minutes Fuller, Smith & Turner PLC: Transaction in own shares
